Purpose of review: To review recent advances in pathogenesis and treatment of conjunctival inflammatory disorders.
Recent findings: The conjunctiva becomes inflamed in a number of conditions, including allergy, atopy, dry eye, mucus membrane pemphigoid, Stevens-Johnson syndrome and surgical manipulation. Basic and clinical studies have identified a number of inflammatory mediators as potential therapeutic targets in these conditions. Additionally, new therapeutic agents and enhanced delivery systems have been evaluated.
Summary: Increased understanding of the key mediators of conjunctival inflammation coupled with improved drug delivery methods are leading to more effective therapy for conjunctival inflammatory disorders.
aOcular Surface Center, Department of Ophthalmology, Baylor College of Medicine, Houston, Texas, USA
bBiological Sciences, Allergan, Inc., Irvine, California, USA
Correspondence to Stephen C. Pflugfelder, MD, Cullen Eye Insititute, 6565 Fannin, NC 205, Houston, TX 77030, USA fax: +1 713 798 1457; e-mail: email@example.com